What Ozempic is

If you have heard the name in the news or from friends, you may be wondering what this medicine actually is and how it behaves in the body. Ozempic is a brand name for a medicine called semaglutide. Semaglutide belongs to a group of medicines known as GLP-1 receptor agonists, sometimes shortened to GLP-1 medicines. In the UK, Ozempic is licensed for the treatment of type 2 diabetes, and it is given as a once-weekly injection under the skin using a pre-filled pen.

The term GLP-1 stands for glucagon-like peptide-1, which is a hormone your gut naturally releases after you eat. Semaglutide is designed to act in a similar way to this natural hormone, which is why medicines like it are described as mimicking GLP-1. Understanding that starting point makes the rest of the picture much easier to follow, so let's look at what GLP-1 does and why it matters.

How GLP-1 affects appetite and blood sugar

Your body releases GLP-1 in response to food. This hormone has several jobs, and GLP-1 medicines are thought to work by supporting those same actions over a longer period than the natural hormone, which tends to break down quickly.

There are a few interconnected effects worth understanding:

  • Helping to regulate blood sugar. GLP-1 encourages the pancreas to release insulin when blood sugar is rising, for example after a meal, and it helps reduce the amount of glucose the liver releases. This is the main reason semaglutide is used in type 2 diabetes, where blood sugar control is the central concern.
  • Slowing stomach emptying. GLP-1 medicines slow the rate at which the stomach passes food into the small intestine. This can help you feel fuller for longer after eating, and it may also explain why some people notice digestive symptoms, particularly early on.
  • Reducing appetite. GLP-1 receptors are found in areas of the brain involved in appetite and the sense of fullness. By acting on these, GLP-1 medicines may reduce feelings of hunger and help some people feel satisfied with less food.

These actions tend to work together rather than in isolation. The blood-sugar effect is why the medicine is licensed for diabetes, while the appetite and fullness effects are the reason GLP-1 medicines have drawn so much interest in the context of weight management. That naturally raises a question about licensing, which is worth being clear about.

Its licensed use (type 2 diabetes) vs weight management context

This is an area where precision genuinely matters, because the same active ingredient appears under different brand names for different purposes. In the UK, Ozempic (semaglutide) is licensed by the MHRA for the treatment of type 2 diabetes. It is not a licensed weight-loss product in the UK, even though it contains the same active ingredient that features in weight-management conversations.

When semaglutide is prescribed specifically for weight management in the UK, this is typically under a different brand called Wegovy, which is a separate product with its own licence, dosing and criteria. NICE has published guidance on where semaglutide for weight management fits within NHS care, and access can depend on factors such as your weight, related health conditions and local services. The key point for patient understanding is that Ozempic and Wegovy are not interchangeable simply because they share an active ingredient; they are licensed for different uses.

You may also come across other GLP-1 based medicines and hear them discussed together. If you would like a broader overview of how these injectable treatments are intended to work, our article on How does a weight-loss injection work? covers the general principles in plain English. Because the licensing details can be confusing, a UK-registered clinician will advise based on your individual circumstances and explain which product, if any, is appropriate for you.

What to realistically expect, and the role of diet and activity

It is understandable to want a clear sense of what a medicine like this might do. What we can say responsibly is that GLP-1 medicines are designed to work alongside your everyday habits rather than in place of them. They are not intended as a standalone solution, and they are not a shortcut that removes the need for other changes.

In practice, this means that any treatment involving semaglutide is generally intended to sit within a wider plan. That plan usually includes:

  • A balanced eating pattern suited to your needs and preferences.
  • Regular physical activity within your ability.
  • Ongoing review with a healthcare professional to check how you are getting on.

Individual responses vary, and it is not possible to promise any particular outcome, timeframe or amount of change. Some people also find that the slower stomach emptying naturally changes how they eat, for example feeling full sooner. None of this replaces the value of sustainable, everyday habits, which tend to matter over the long term regardless of whether a medicine is involved.

Why habits still matter

Because GLP-1 medicines influence appetite and fullness, they can make certain changes feel more manageable, but the underlying eating pattern and activity level remain important. Working with a clinician means these elements can be tailored to you rather than following a one-size-fits-all approach, and it allows the plan to be adjusted over time.

Safety and clinician oversight

Semaglutide is a prescription-only medicine in the UK, and this is an important safeguard rather than an obstacle. Being prescription-only means a suitably qualified prescriber assesses whether a treatment is appropriate for you, taking into account your medical history, any other medicines you take and your individual health goals.

Like all medicines, GLP-1 treatments can cause side effects. Digestive symptoms such as nausea are among those commonly discussed, and these are often more noticeable when starting or when a dose is increased. If you would like to understand these in more detail, our overview of Common side effects of GLP-1 medications explains what people frequently report and why. It is always worth discussing any concerns with your prescriber or pharmacist.

People sometimes compare different GLP-1 based options they have heard about, such as those containing tirzepatide, and want to know how safety is assessed. If that is on your mind, you may find our article Is Mounjaro safe? a helpful companion piece, as it walks through how questions of safety are approached for this class of medicines more broadly.

The most reliable path is a proper assessment. Because your health, history and circumstances are unique to you, a UK-registered clinician will advise based on your individual circumstances, confirm whether a treatment is suitable, explain the correct use of the pen, and arrange appropriate follow-up. This article is intended as general patient education to help you understand how the medicine is thought to work; it is not a recommendation to start any particular treatment.

Bringing it together

In short, Ozempic is a brand of semaglutide, a GLP-1 receptor agonist licensed in the UK for type 2 diabetes. It works by supporting the actions of a natural gut hormone: helping to regulate blood sugar, slowing stomach emptying and reducing appetite. When semaglutide is used for weight management in the UK, this is typically under the Wegovy brand, and any use is prescription-only and guided by a clinician alongside diet and activity. If you are considering your options, a conversation with a qualified prescriber is the sensible next step.